Previously, we found that Src and MET were upstream kinases of TOPK, and the phosphorylation of TOPK by Src and MET promoted the tumorigenesis of colon cancer and resistance of NSCLC to gefitinib, respectively [17, 18]. Here, MET is linked to malignant colon neoplasm.